Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tongshu Biotechnology Raises $78 Million for Early Cancer Screening Tests

publication date: Nov 26, 2021

Changzhou Tongshu Biotechnology raised $78 million in a C round to support its gene testing products for cancer diagnoses, which are based on multiple innovative platforms. Founded in 2016, Tongshu Gene has developed IVD products that use ctDNA for early cancer screening tests. It will use the capital to continue developing its products and to build direct sales channels to more than 500 tertiary hospitals. The round was led by GL Capital Group, Broad Vision Funds and Oceanpine Capital. It included new investors Jinyuan Capital, Haichuang Fund of Funds and Yinhe Yuanhui Investment. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital